Literature DB >> 32030000

Down's Syndrome Screening in the First Trimester with Additional Serum Markers: Indian Parameters.

Seshandri Suresh1, Howard S Cuckle2, Sujatha Jagadeesh1, Kushagradhi Ghosh3, Gayathri Vemavarapu4, Tulika Taval4, Sudarshan Suresh1.   

Abstract

OBJECTIVE: To derive a risk calculation algorithm suitable for use in India when screening for Down's syndrome using four first-trimester maternal serum markers either alone or with ultrasound nuchal translucency (NT).
METHODS: Stored maternal serum samples (- 20 °C) from 411 singleton unaffected pregnancies were retrieved and measured for pregnancy-associated plasma protein (PAPP-A), free β-human chorionic gonadotropin (hCG), placental growth factor and α-fetoprotein. Samples were taken at 10-13 weeks' gestation. Equations were derived to express marker levels in multiples of the gestation-specific normal median, adjusted for maternal weight. Gaussian model parameters were derived and compared with six published non-Indian studies; NT parameters were derived from 27,647 women screened in India. On the basis of the maternal age distribution in 64,473 Indian women screened in 2016-2017, the model was used to predict test performance.
RESULTS: The model predicted a detection rate for a serum-only protocol of 80% for a 5% false-positive rate. Using a 1 in 250 at term Down's syndrome risk cut-off, the predicted detection rate was 78% and the false-positive rate was 4.1%. When NT was also included, the rates were 95% for 5% and 90% for 1.4%, respectively.
CONCLUSION: First-trimester screening using four serum markers only can be carried out in India. Performance is expected to be similar to the second-trimester Quad test and will also facilitate early screening for preeclampsia and open spina bifida. A protocol of NT plus the four serum markers enhances the performance compared with NT, PAPP-A and free β-hCG. © Federation of Obstetric & Gynecological Societies of India 2019.

Entities:  

Keywords:  AFP; Down’s syndrome; First trimester; PlGF; Prenatal diagnosis; Screening

Year:  2019        PMID: 32030000      PMCID: PMC6982611          DOI: 10.1007/s13224-018-1198-1

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  8 in total

1.  First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA.

Authors:  J Johnson; M Pastuck; A Metcalfe; G Connors; R Krause; D Wilson; H Cuckle
Journal:  Prenat Diagn       Date:  2013-08-06       Impact factor: 3.050

2.  First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor, and α-fetoprotein.

Authors:  Tianhua Huang; Alan Dennis; Wendy S Meschino; Shamim Rashid; Ellen Mak-Tam; Howard Cuckle
Journal:  Prenat Diagn       Date:  2015-05-19       Impact factor: 3.050

3.  Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.

Authors:  N O'Gorman; D Wright; L C Poon; D L Rolnik; A Syngelaki; A Wright; R Akolekar; S Cicero; D Janga; J Jani; F S Molina; C de Paco Matallana; N Papantoniou; N Persico; W Plasencia; M Singh; K H Nicolaides
Journal:  Ultrasound Obstet Gynecol       Date:  2017-05-14       Impact factor: 7.299

4.  First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.

Authors:  D Wright; A Syngelaki; I Bradbury; R Akolekar; K H Nicolaides
Journal:  Fetal Diagn Ther       Date:  2013-12-18       Impact factor: 2.587

5.  Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures.

Authors:  Glenn E Palomaki; Elizabeth E Eklund; Louis M Neveux; Geralyn M Lambert Messerlian
Journal:  Prenat Diagn       Date:  2015-06-01       Impact factor: 3.050

6.  Maternal serum placental growth factor and α-fetoprotein testing in first trimester screening for Down syndrome.

Authors:  Kim Donalson; Steve Turner; Lesley Morrison; Päivi Liitti; Christel Nilsson; Howard Cuckle
Journal:  Prenat Diagn       Date:  2013-03-26       Impact factor: 3.050

7.  Combined screening for open spina bifida at 11-13 weeks using fetal biparietal diameter and maternal serum markers.

Authors:  Jean-Pierre Bernard; Howard S Cuckle; Maguy A Bernard; Christine Brochet; Laurent J Salomon; Yves Ville
Journal:  Am J Obstet Gynecol       Date:  2013-05-11       Impact factor: 8.661

8.  Expanded conventional first trimester screening.

Authors:  Jonathan B Carmichael; Hsiao-Pin Liu; David Janik; Terrence W Hallahan; Kypros H Nicolaides; David A Krantz
Journal:  Prenat Diagn       Date:  2017-07-18       Impact factor: 3.050

  8 in total
  1 in total

1.  Predicting Hypertensive Disease in the First Trimester of Pregnancy: Risk Models and Analysis of Serum D-dimer Levels Combined with Plasma Pregnancy-Associated Protein A, Free β-Subunit of Human Chorionic Gonadotropin, and Fetal Nuchal Translucency.

Authors:  Yiming Chen; Wenwen Ning; Xuelian Chu; Yijie Chen; Linyuan Gu; Zhen Xie; Liyao Li; Caihe Wen; Xiaoying Wang
Journal:  Biomed Res Int       Date:  2022-03-30       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.